AtaiBeckley Inc. 4

Chief Legal and Business Officer Christopher Ryan Cave Barrett had all his AtaiBeckley Inc. common stock, stock options, and RSUs cancelled for cash and CVRs at a $6.75 per-share merger price in connection with Eli Lilly’s acquisition of the company.

On September 11, 2026, in connection with the closing of Eli Lilly and Company's acquisition of AtaiBeckley Inc., Chief Legal and Business Officer Christopher Ryan Cave Barrett had all of his equity interests in the company—155,066 shares of common stock, 3,369,267 shares underlying multiple stock option grants with exercise prices ranging from $1.18 to $5.68, and 150,000 restricted stock units—automatically cancelled and converted into the right to receive cash and contingent value rights (CVRs). Each common share was converted into $6.75 in cash plus one CVR (with up to $2.50 additional cash per CVR subject to clinical and regulatory milestones), each stock option into cash equal to the in-the-money value based on a $6.75 merger price plus one CVR per underlying share, and each RSU into $6.75 in cash per unit plus one CVR per unit, all subject to applicable tax withholding; following the merger, Barrett no longer directly owns AtaiBeckley equity as it became a wholly owned subsidiary of Eli Lilly.

Filing Facts

CIK

2081043

Ticker

ATAI

Form

4

Source Type

fda

Accession

0001140361-26-036387

Alert Tier

5